|
CTRCD (n = 13)
|
No CTRCD (n = 59)
|
p value
|
---|
LVEDVI (mL/m2)
|
56.8 ± 10.6
|
56.5 ± 9.9
|
0.920
|
LVESVI (mL/m2)
|
19.9 ± 5.3
|
20.3 ± 4.6
|
0.774
|
LVEF (%)
|
65.0 ± 6.4
|
63.9 ± 5.9
|
0.564
|
LVGLS (%)
|
−21.0 ± 2.4
|
−22.2 ± 2.2
|
0.086
|
E (cm/sec)
|
71.3 ± 10.4
|
62.7 ± 7.7
|
0.001
|
e’ (cm/sec)
|
8.8 ± 1.4
|
8.3 ± 1.8
|
0.379
|
s’ (cm/sec)
|
7.9 ± 0.9
|
7.4 ± 1.0
|
0.138
|
E/e’
|
8.2 ± 1.0
|
7.7 ± 1.2
|
0.201
|
LAVI (mL/m2)
|
25.8 ± 3.8
|
26.0 ± 3.9
|
0.833
|
PALS (%)
|
33.1 ± 5.9
|
33.8 ± 5.6
|
0.689
|
LA conduit strain (%)
|
19.2 ± 3.4
|
19.8 ± 3.3
|
0.550
|
LA booster strain (%)
|
13.9 ± 2.5
|
14.0 ± 2.3
|
0.905
|
RVSP (mmHg)
|
29.3 ± 7.1
|
32.0 ± 7.3
|
0.239
|
- CTRCD cancer therapeutics-related cardiac dysfunction, LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVGLS left ventricular global longitudinal strain, E early diastolic mitral inflow velocity, e’: early diastolic velocity of mitral septal annulus, s’: systolic velocity of mitral septal annulus, LAVI left atrial volume index, PALS peak atrial longitudinal strain, LA left atrium, RVSP right ventricular systolic pressure